NASDAQ
HALO
Last Price
US $75.05
KEY FIGURES
MKT CAP
$8.9B
EPS
TTM
$2.95
PEG
TTM
N/M
P/E
TTM
25.42x
P/S
TTM
5.88x
YIELD
0.00%
GROWTH
Revenue Y/Y
Profit margin
Current Ratio
Capital Returns
126.27%
Return on equity
ROIC: 23.65%
Valuation History
26.1X
Price to Earnings
EV/EBITDA: 17.4X
Cash flow
Profit margin
39.16%
(FY vs FY)
EBITDA Y/Y
30.23%
(FY vs FY)
Cash flow Y/Y
64.85%
(FY vs FY)
Cash Flow (DCF)
Fair Value
Market $75.05
30.19%
Default assumptions
EBITDA Multiple
Fair Value
Market $75.05
-27.29%
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.
Valuation
Financial
Performance
Financial stability - Cash flow debt coverage.
Halozyme Therapeutics, Inc. cash flow to debt ratio of 30.41% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.
Financial stability - Healthy cash flow growth.
Halozyme Therapeutics, Inc.'s free cash flow has increased 37.62% from $468.37M last year to $644.59M, signaling increasing performance
Financial risk - Healthy debt to equity ratio.
Halozyme Therapeutics, Inc.'s debt to equity ratio is 9.76, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy
Financial risk - Healthy debt to equity ratio development.
Halozyme Therapeutics, Inc.'s debt has increased relative to shareholder equity from 4.14 last year to 9.76 today, signaling weakened financials
Financial risk - Net debt/EBITDA.
Halozyme Therapeutics, Inc. has a net debt to EBITDA ratio of 3.51x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk
Financial stability - ICR.
Halozyme Therapeutics, Inc.'s interest coverage ratio of 44.97 indicates that earnings with good margin can cover interest payments on company debt
Financial risk - Profit margin growth.
Halozyme Therapeutics, Inc.'s profit margin has decreased (-47.13%) in the last year from 43.74% to 23.13%, signaling decreasing performance
Financial stability - Short term assets vs short term liabilities.
Halozyme Therapeutics, Inc.'s short-term assets of $825.21M exceed its short-term liabilities of $177.09M
Increasing performance - ROA.
Halozyme Therapeutics, Inc.'s return on assets of 13.05% is higher than the 5.00% threshold, indicating efficient asset utilization
Increasing performance - Absolute return on equity.
Halozyme Therapeutics, Inc.'s return on equity of 126.27%, is higher than 15.00%, indicating good performance
Increasing performance - Earnings quality.
Halozyme Therapeutics, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation
Increasing performance - Earnings stability.
Halozyme Therapeutics, Inc. had positive net income in 5.00 out of 5 years, indicating stable and consistent earnings
Increasing performance - Free cash flow.
Halozyme Therapeutics, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures
Increasing performance - FCF yield.
Halozyme Therapeutics, Inc. has a free cash flow yield of 7.24%, which is above the 2.00% threshold, indicating strong cash generation relative to market value
Decreasing performance - Healthy earnings growth.
Halozyme Therapeutics, Inc.'s yearly earnings has decreased -28.64% since last year from $444.09M to $316.89M, signaling decreasing performance
Increasing performance - Healthy revenue growth.
Halozyme Therapeutics, Inc.'s yearly revenue has increased 37.55% since last year from $1.02G to $1.40G, signaling increasing performance
Increasing performance - ROIC.
ROIC 23.65% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.
Increasing performance - 3-year revenue CAGR.
Halozyme Therapeutics, Inc.'s 3-year revenue CAGR of 28.38% is positive, indicating growing revenue over the past 3 years
Increasing performance - Revenue consistency.
Halozyme Therapeutics, Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance
Increasing performance - ROE consistency.
Halozyme Therapeutics, Inc. had positive ROE in 5.00 out of 5 years, indicating consistent and reliable returns on equity
Undervalued - DCF valuation.
Halozyme Therapeutics, Inc. is undervalued relative to its fair value price of 97.71 based on Discounted Cash Flow model
Overvalued - Earnings yield.
Halozyme Therapeutics, Inc. has an earnings yield of 3.93%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings
Overvalued - EBITDA valuation.
Halozyme Therapeutics, Inc. is overvalued relative to its fair value price of 54.57 based on EBITDA multiple model
Undervalued - EV/EBITDA.
Halozyme Therapeutics, Inc. has an EV/EBITDA ratio of 19.04x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings
Overvalued - PEG ratio value.
Halozyme Therapeutics, Inc. has no meaningful EPS growth rate; PEG ratio cannot be computed.
Overvalued - P/B ratio.
Halozyme Therapeutics, Inc. has a price-to-book ratio of 40.37x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value
Undervalued - P/S ratio.
Halozyme Therapeutics, Inc. has a price-to-sales ratio of 5.88x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue